Published October 2018 | Version v1
Journal article

68Ga-PSMA-617 PET/CT. A promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients

  • 1. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Beijing (China)
  • 2. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Beijing (China)
  • 3. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Beijing (China)
  • 4. Beijing Hospital, Department of Urology, Beijing (China)
  • 5. Peking University First Hospital, Department of Urology, Beijing (China)
  • 6. Peking University First Hospital, Department of Nuclear Medicine, Beijing (China)
  • 7. Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Ultrasonography, Beijing (China)

Description

The purpose of this study was to investigate the performance of 68Ga-PSMA-617 PET/CT in predicting risk stratification and metastatic risk of prostate cancer. Fifty newly diagnosed patients with prostate cancer as confirmed by needle biopsy were continuously included, 40 in a train set and ten in a test set. 68Ga-PSMA-617 PET/CT and clinical data of all patients were retrospectively analyzed. Semi-quantitative analysis of PET images provided maximum standardized uptake (SUVmax) of primary prostate cancer and volumetric parameters including intraprostatic PSMA-derived tumor volume (iPSMA-TV) and intraprostatic total lesion PSMA (iTL-PSMA). According to prostate cancer risk stratification criteria of the NCCN Guideline, all patients were simplified into a low-intermediate risk group or a high-risk group. The semi-quantitative parameters of 68Ga-PSMA-617 PET/CT were used to establish a univariate logistic regression model for high-risk prostate cancer and its metastatic risk, and to evaluate the diagnostic efficacy of the predictive model. In the train set, 30/40 (75%) patients had high-risk prostate cancer and 10/40 (25%) patients had low-to-moderate-risk prostate cancer; in the test set, 8/10 (80%) patients had high-risk prostate cancer while 2/10 (20%) had low-intermediate risk prostate cancer. The univariate logistic regression model established with SUVmax, iPSMA-TV and iTL-PSMA could all effectively predict high-risk prostate cancer; the AUC of ROC were 0.843, 0.802 and 0.900, respectively. Based on the test set, the sensitivity and specificity of each model were 87.5% and 50% for SUVmax, 62.5% and 100% for iPSMA-TV, and 87.5% and 100% for iTL-PSMA, respectively. The iPSMA-TV and iTL-PSMA-based predictive model could predict the metastatic risk of prostate cancer, the AUC of ROC was 0.863 and 0.848, respectively, but the SUVmax-based prediction model could not predict metastatic risk. Semi-quantitative analysis indexes of 68Ga-PSMA-617 PET/CT imaging can be used as ''imaging biomarkers'' to predict risk stratification and metastatic risk of prostate cancer. (orig.)

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00259-018-4037-9

Additional details

Identifiers

Publishing Information

Journal Title
European Journal of Nuclear Medicine and Molecular Imaging
Journal Volume
45
Journal Issue
11
Journal Page Range
p. 1852-1861
ISSN
1619-7070
CODEN
EJNMA6